Tissue Regenix Group PLC Result of AGM (4217J)

TIDMTRX

RNS Number : 4217J

Tissue Regenix Group PLC

26 April 2022

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

Result of AGM

Tissue Regenix Group (AIM:TRX), the regenerative medical devices company, announces that at the AGM held earlier today, all resolutions were duly passed on a show of hands.

The results of the poxy are set out below:

 
 Resolution                  In favour       %       Against      %   Withheld 
 1            Ordinary   3,096,432,946   99.87     4,000,000   0.13    859,285 
             ---------  --------------          ------------  -----  --------- 
 2            Ordinary   3,091,355,706   99.71     9,104,066   0.29    832,459 
             ---------  --------------          ------------  -----  --------- 
 3            Ordinary   3,096,355,706   99.87     4,104,066   0.13    832,459 
             ---------  --------------          ------------  -----  --------- 
 4            Ordinary   3,091,355,706   99.71     9,104,066   0.29    832,459 
             ---------  --------------          ------------  -----  --------- 
 5            Ordinary   3,091,355,706   99.71     9,104,066   0.29    832,459 
             ---------  --------------          ------------  -----  --------- 
 6            Ordinary   3,091,355,706   99.71     9,104,066   0.29    832,459 
             ---------  --------------          ------------  -----  --------- 
 7            Ordinary   3,091,355,706   99.71     9,104,066   0.29    832,459 
             ---------  --------------          ------------  -----  --------- 
 8            Ordinary   3,096,379,267   99.87     4,080,505   0.13    832,459 
             ---------  --------------          ------------  -----  --------- 
 9            Ordinary   3,096,379,267   99.87     4,080,505   0.13    832,459 
             ---------  --------------          ------------  -----  --------- 
 10           Ordinary   3,090,580,199   99.68     9,826,573   0.32    885,459 
             ---------  --------------          ------------  -----  --------- 
 11            Special   3,059,344,373   98.68    41,062,399   1.32    885,459 
             ---------  --------------          ------------  -----  --------- 
 12            Special   3,085,499,489   99.49    15,789,742   0.51      3,000 
             ---------  --------------          ------------  -----  ---------

NB: Percentage of Votes case excludes Withheld votes

The full text of the resolutions passed at the AGM may be found in the Notice of AGM published on 15 March 2022

For more information:

 
 Tissue Regenix Group plc                                    www.tissueregenix.com 
  David Cocke, Chief Financial Officer                             Via Walbrook PR 
 
 Stifel Nicolaus Europe Limited (Nominated Adviser         Tel: +44(0)20 7710 7600 
  and Broker) 
  Ben Maddison / Nick Harland 
 Walbrook PR Ltd                                          Tel: +44 (0)20 7933 8780 
  Alice Woodings / Lianne Applegarth                  TissueRegenix@walbrookpr.com

About Tissue Regenix (www.tissuergenix.com)

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs such as in sports medicine, foot and ankle, and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies(R), a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, dental, and ophthalmological surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSEMFIMEESEFL

(END) Dow Jones Newswires

April 26, 2022 11:19 ET (15:19 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024